Galenica Will Leverage Aspreva Acquisition To Strengthen Specialty Pharma Group
This article was originally published in The Pink Sheet Daily
Swiss drug company seeks to buy Aspreva for roughly $915 million to accelerate development of its pharma arm.
You may also be interested in...
Biogen brings Tysabri fully in-house by using off-shore cash to compensate Irish partner Elan. Plus, the week in biopharma deal-making.
Aspreva continues Phase III trial of CellCept to treat autoimmune disease pemphigus vulgaris.
Firm is focusing the iron replacement therapy on the women’s health market, including heavy uterine bleeding and postpartum.